908 Devices Earnings Call Transcripts
Fiscal Year 2026
-
The company completed a strategic transformation, focusing on handheld analytical devices and expanding its product suite, including the innovative VipIR and XplorIR. Strong financial performance in 2025, recurring revenue growth, and operational improvements position the business for 15%-20% revenue growth in 2026 and sustainable profitability in the coming years.
-
Demand is rising due to global unrest and increased defense spending, with international revenues growing and robust U.S. government funding. Product innovation and recurring revenue are driving growth, while margin improvements and strategic investments support a path to profitability by 2027.
-
Reported 18% revenue growth and positive adjusted EBITDA, driven by handheld detection tools and strong state/local demand. VipIR and other products are fueling 2026 guidance of 15–20% growth, with recurring revenue and software initiatives like TeamLeader set to enhance predictability.
Fiscal Year 2025
-
Q4 and full year 2025 saw strong revenue growth, margin expansion, and a return to positive Adjusted EBITDA, driven by FTIR product adoption, recurring revenue, and operational efficiencies. 2026 guidance projects 15%-20% revenue growth, with continued focus on innovation and profitability.
-
A major transformation has refocused the business on handheld chemical detection for public safety and defense, driving 16% YTD revenue growth and improved margins. New product launches, strong state/local sales, and robust recurring revenue support a 20%+ growth outlook for 2026, with key catalysts including equipment modernization, NextGen MX908, and the DOD AFCAD program.
-
Q3 saw strong revenue and portfolio expansion following a major acquisition and divestiture, with a focus on handheld detection devices. Growth is driven by state/local demand, new product launches, and government partnerships, with profitability and 20% growth targeted for 2026.
-
Q3 revenue was $14M, down 4% YoY but up 8% sequentially, with strong FTIR device demand and improved adjusted EBITDA loss. 2025 guidance remains $54–$56M, targeting positive adjusted EBITDA in Q4, though ~$4M in Q4 revenue is at risk if government delays persist.
-
Transitioned to a focused public safety and defense tech company, expanding its handheld product portfolio and strengthening financials. Projecting accelerated growth, driven by global security needs, new product launches, and robust funding, with profitability targeted for 2026.
-
Q2 2025 saw 14% revenue growth, record device placements, and improved adjusted EBITDA loss, with strong momentum from new product launches and favorable legislative funding. Guidance for 2025 was raised, targeting adjusted EBITDA positivity by Q4 and over 20% revenue growth in 2026.
-
A strategic transformation has refocused operations on handheld chemical detection, driving strong revenue growth, margin improvement, and a clear path to profitability by Q4 2025. Growth is fueled by new products, global demand, and robust public funding, with innovation and customer support as key differentiators.
-
Q1 2025 revenue grew 59% year-over-year to $11.8 million, driven by strong handheld device sales and recurring revenue. The company completed a strategic transformation, strengthened its balance sheet, and reiterated 2025 guidance of $53–$55 million revenue, targeting profitability by Q4.
-
A major portfolio transformation is underway, with a $70 million divestiture fueling a focus on high-growth handheld markets and accelerating profitability. International and government demand is rising, supported by new product launches and a diversified customer base.
-
A major portfolio divestiture and renewed focus on handheld devices position the company for accelerated growth, improved margins, and profitability by late 2025. Product innovation, international expansion, and cross-selling drive future opportunities, with execution on transformation plans a top priority.
Fiscal Year 2024
-
Divestiture of the desktop portfolio to Repligen for $70 million sharpens focus on high-growth handheld markets, with 2024 revenue up 19% and strong recurring revenue growth. Guidance calls for 11–15% revenue growth in 2025, accelerating above 20% in 2026, with profitability and cash flow milestones ahead.
-
Point-of-need chemical detection and forensic handhelds drive growth, with portfolio expansion and the RedWave acquisition enabling broader analyte coverage and cross-selling. Bioprocessing devices face longer sales cycles but are supported by new products and partnerships. Manufacturing relocation and cost reductions are set to improve margins in 2026.
-
Q3 revenue grew 17% year-over-year to $16.8M, but fell short of expectations due to delayed government and international orders. 2024 revenue guidance was lowered, with cost-saving measures and manufacturing consolidation underway to drive future margin expansion and growth.
-
Handheld products drove strong Q2 growth, while desktop sales faced CapEx headwinds. The RedWave acquisition expanded technology and revenue, with synergies expected to boost margins and growth. Focus remains on innovation, recurring revenue, and leveraging partnerships for future acceleration.
-
Q2 revenue grew 16% year-over-year to $14 million, driven by strong handheld sales and the RedWave acquisition, while desktop revenues declined amid ongoing macro pressures. Gross margin improved, and 2024 guidance was reiterated at $63–$65 million, with a focus on handheld growth and strategic partnerships.
-
Achieved strong revenue growth and expanded global device placements, with recurring revenues and a diversified customer base. The RedWave acquisition adds profitable, complementary technology, accelerating growth, margin improvement, and market reach. Large opportunities in forensics and bioprocessing support a robust outlook.